NASDAQ$HUMA

Humacyte Inc · Q4 2025 earnings

Q4 2025 earnings · · Before market open · Investor relations

Reports awaiting report

Humacyte hasn't published Q4 2025 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.

  • Most recent report

    Q1 2026

    Revenue
    $495K
    EPS
    -$0.09
  • Year-ago · Q4 2024

    Q4 2024

    Revenue
    $0.00
    EPS
    -$0.16
  • FY2025 consensus

    Analyst consensus

    Revenue
    $9.53M
    EPS
    -$0.86

Revenue & EPS history

Humacyte · Revenue · Quarterly

$495K

Q1 2026-4.3%vs Q1 2025
Beat estimate in 2 of 15 quarters(13%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

+5.1%

Avg return

Earnings day

+2.0%

Avg return

5 days after

+3.5%

Avg return

30 days after

62%

13 / 21 earnings

Positive

+37.0%

Q2 2023

Best reaction

-30.1%

Q2 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+22.9%-1.5%+15.2%
Q4 2025-15.1%-25.1%-33.0%
Q3 2025-3.2%-11.7%+2.3%
Q2 2025-30.1%-24.2%-40.3%
Q1 2025+19.5%+23.8%+25.4%
Q4 2024-2.5%-27.4%-28.4%
Q3 2024+4.9%+1.5%-8.2%
Q1 2024+21.2%+43.1%+60.8%
Q4 2023-12.8%-13.9%+2.8%
Q3 2023+7.3%+9.1%+27.9%
Q2 2023+37.0%+8.9%+19.0%
Q1 2023-6.1%-2.5%+1.1%
Q4 2022+4.9%-1.3%+7.1%
Q3 2022+2.2%-5.4%-4.5%
Q2 2022+8.6%+9.1%+2.5%
Q1 2022-9.5%-12.7%-18.8%
Q4 2021+14.1%+12.2%+16.5%
Q2 2021+14.1%+12.2%+16.5%
Q3 2021+9.0%+18.4%+4.0%
Q1 2021+0.0%+0.0%+4.9%
Q4 2020+21.2%+28.4%+1.5%
Q3 2020———

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro